Skip to main content
. 2014 Sep 28;3(9):823–833. doi: 10.1016/j.molmet.2014.09.005

Figure 7.

Figure 7

Central exendin-4 decreases weight and food consumption and decreases both fasting hypertriglyceridemia and VLDL-associated lipid and apoB100 levels. (A) Fructose-fed hamsters received intracerebroventricular (ICV) vehicle or exendin-4 (250 μg) and FPLC analysis was carried out. (B) Total change in weight. (C,D) Changes in food consumption and fasting plasma TG levels before (Day 0) and after (Day 14) the diet/treatment. (E–G) Triglyceride (TG), cholesterol and apoB100. n = 8; *p < 0.05, ***p < 0.001. Analyzed by two-way ANOVA with Bonferroni post hoc test (C,D) or by Student's unpaired t-test (B).